HIV pre-exposure prophylaxis in transgender women: A subgroup analysis of the iPrEx trial

BACKGROUND: Oral emtricitabine-tenofovir disoproxil fumarate (FTC/TDF) pre-exposure prophylaxis (PrEP) is used to prevent the sexual acquisition of HIV. Transgender women (TGW) have unique characteristics that may relate to PrEP use, effectiveness, and safety. METHODS: The iPrEx trial was a randomiz...

Descripción completa

Detalles Bibliográficos
Autores principales: Deutsch, Madeline B., Glidden, David V., Sevelius, Jae, Keatley, Joanne, McMahan, Vanessa, Guanira, Juan, Kallas, Esper G., Chariyalertsak, Suwat, Grant, Robert M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5111857/
https://www.ncbi.nlm.nih.gov/pubmed/26614965
http://dx.doi.org/10.1016/S2352-3018(15)00206-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5111857/
https://www.ncbi.nlm.nih.gov/pubmed/26614965
http://dx.doi.org/10.1016/S2352-3018(15)00206-4

Ejemplares similares